These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31474225)

  • 1. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.
    Bach P; Hartung D
    Addict Sci Clin Pract; 2019 Sep; 14(1):30. PubMed ID: 31474225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opioid crisis: Origins, trends, policies, and the roles of pharmacists.
    Chisholm-Burns MA; Spivey CA; Sherwin E; Wheeler J; Hohmeier K
    Am J Health Syst Pharm; 2019 Mar; 76(7):424-435. PubMed ID: 31361827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opiate use disorders and overdose: Medical students' experiences, satisfaction with learning, and attitudes toward community naloxone provision.
    Tobin H; Klimas J; Barry T; Egan M; Bury G
    Addict Behav; 2018 Nov; 86():61-65. PubMed ID: 29198489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naloxone for Opioid Overdose and the Role of the Pharmacist.
    Toderika Y; Williams S
    Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
    Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
    Palmer E; Hart S; Freeman PR
    J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm Reduction Strategies for the Opiod Crisis.
    Castillo T
    N C Med J; 2018; 79(3):192-194. PubMed ID: 29735629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies and policies to address the opioid epidemic: A case study of Ohio.
    Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
    J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.